N2OFF: KDJ Death Cross on 15min chart with Bearish Marubozu Candle.

The 15-minute chart for N2OFF has exhibited a KDJ Death Cross and a bearish Marubozu pattern on September 30, 2025, at 15:15. This indicates a shift in the momentum of the stock price towards a downward trend, with a potential for further decline. Sellers are currently dominating the market, and it is likely that this bearish momentum will continue.

The stock of N2OFF, Inc. (NASDAQ: NITO) experienced a significant shift in momentum on September 30, 2025, at 15:15, according to the 15-minute chart. The chart indicated a KDJ Death Cross and a bearish Marubozu pattern, suggesting a potential downward trend for the stock price. This technical analysis signals that sellers are currently dominating the market, and it is likely that this bearish momentum will continue.

The KDJ Death Cross is a technical indicator that occurs when the K line (a moving average of the stock price) crosses below the D line (a moving average of the stock price's momentum). This pattern is often associated with a change in the stock's momentum from bullish to bearish. The Marubozu pattern, characterized by a stock closing at its high or low for the day, can further confirm a trend reversal.

This bearish signal comes at a critical time for N2OFF, as its shareholders recently approved the acquisition of SciSparc’s majority-owned subsidiary, MitoCareX Bio Ltd. SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition^[1] The approval, which came during a special meeting on September 25, 2025, is a crucial milestone towards completing the acquisition, which would make MitoCareX a wholly owned subsidiary of N2OFF. However, the stock's bearish momentum may impact the overall perception of N2OFF's financial health and growth prospects.

Investors should closely monitor the stock's performance and technical indicators in the coming weeks to gauge the potential impact of the bearish momentum on N2OFF's stock price. The global cancer therapeutics and biotherapeutics market, which MitoCareX operates in, was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031 , suggesting a significant growth opportunity for the company.